(Q38310521)

2 September 2017

title

Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine (English)

1 reference

2 September 2017

0 references

1 reference

15

Lorne A Babiuk

1 reference

2 September 2017

6

George Mutwiri

1 reference

2 September 2017

author name string

Alexander N Zakhartchouk

1

1 reference

2 September 2017

Chetna Sharon

2

1 reference

2 September 2017

Malathy Satkunarajah

3

1 reference

2 September 2017

Thierry Auperin

4

1 reference

2 September 2017

Sathiyanarayanan Viswanathan

5

1 reference

2 September 2017

Martin Petric

7

1 reference

2 September 2017

Raymond H See

8

1 reference

2 September 2017

Robert C Brunham

9

1 reference

2 September 2017

B Brett Finlay

10

1 reference

2 September 2017

Cheryl Cameron

11

1 reference

2 September 2017

David J Kelvin

12

1 reference

2 September 2017

Alan Cochrane

13

1 reference

2 September 2017

James M Rini

14

1 reference

2 September 2017

language of work or name

English

0 references

publication date

2 August 2006

1 reference

2 September 2017

number of pages

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

2 September 2017

volume

25

1 reference

2 September 2017

issue

1

1 reference

2 September 2017

page(s)

136-143

1 reference

Severe acute respiratory syndrome (SARS): a year in review.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

The Genome sequence of the SARS-associated coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Coronavirus spike proteins in viral entry and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Obstacles and advances in SARS vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Molecular advances in the cell biology of SARS-CoV and current disease prevention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

In vivo induction of type 1 and 2 immune responses against protein antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Mechanisms of stimulation of the immune response by aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Preparation and characterization of SARS in-house reference antiserum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.084

Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16919855

12 December 2020

inferred from PubMed ID database lookup

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16919855

12 December 2020

inferred from PubMed ID database lookup

Structure-function relationships in the collagenase family member transin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16919855

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1016/J.VACCINE.2006.06.084

1 reference

2 September 2017

1 reference